Seer Reports Revenue Decline Amid Macroeconomic Headwinds — Seer, Inc.

Event summary

Seer reported $3.1 million in revenue for Q2 2026, a 23% decrease from the prior year period.
The company reaffirmed its full-year 2026 revenue guidance of $16–$18 million, representing 3% growth at the midpoint over 2025.
Seer initiated enforcement of intellectual property rights against Nanomics Biotechnology Co., Ltd. with a U.S. International Trade Commission investigation opened.
The company ended Q2 with approximately $209.5 million in cash, cash equivalents, and investments.

The big picture

Seer's Q2 2026 results highlight the challenges faced by biotech companies in a tightening funding environment. The company's focus on AI-driven proteomics and intellectual property enforcement reflects broader industry trends toward technological differentiation and legal protection of innovative platforms. With $209.5 million in cash reserves, Seer has a financial cushion but must demonstrate revenue growth to justify its market valuation.

What we're watching

Revenue Recovery: Whether Seer can convert scientific leadership into revenue amid continued macroeconomic headwinds and elongated sales cycles.
IP Enforcement: The impact of the U.S. International Trade Commission investigation on Nanomics Biotechnology Co., Ltd. and its potential to strengthen Seer's market position.
Cash Burn Rate: The pace at which Seer depletes its cash reserves, given the negative free cash flow of approximately $25.3 million for the first half of 2026.